MX2011011531A - Acidos nucleicos que se unen a hepcidina. - Google Patents
Acidos nucleicos que se unen a hepcidina.Info
- Publication number
- MX2011011531A MX2011011531A MX2011011531A MX2011011531A MX2011011531A MX 2011011531 A MX2011011531 A MX 2011011531A MX 2011011531 A MX2011011531 A MX 2011011531A MX 2011011531 A MX2011011531 A MX 2011011531A MX 2011011531 A MX2011011531 A MX 2011011531A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acids
- binding nucleic
- hepcidin binding
- hepcidin
- binding
- Prior art date
Links
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title abstract 2
- 102000018511 hepcidin Human genes 0.000 title abstract 2
- 229940066919 hepcidin Drugs 0.000 title abstract 2
- 108060003558 hepcidin Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09006028 | 2009-04-30 | ||
| EP10000635 | 2010-01-22 | ||
| PCT/EP2010/002659 WO2010124874A1 (en) | 2009-04-30 | 2010-04-30 | Hepcidin binding nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011011531A true MX2011011531A (es) | 2012-04-19 |
Family
ID=42374984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011011531A MX2011011531A (es) | 2009-04-30 | 2010-04-30 | Acidos nucleicos que se unen a hepcidina. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8841431B2 (enExample) |
| EP (1) | EP2424985A1 (enExample) |
| JP (1) | JP5798549B2 (enExample) |
| KR (1) | KR20120004487A (enExample) |
| CN (2) | CN104450691A (enExample) |
| AR (1) | AR076518A1 (enExample) |
| AU (1) | AU2010243831B2 (enExample) |
| BR (1) | BRPI1014625A2 (enExample) |
| CA (1) | CA2760244A1 (enExample) |
| EA (1) | EA022539B1 (enExample) |
| IL (1) | IL216010A0 (enExample) |
| MX (1) | MX2011011531A (enExample) |
| SG (2) | SG10201401925VA (enExample) |
| TW (1) | TWI578992B (enExample) |
| WO (1) | WO2010124874A1 (enExample) |
| ZA (1) | ZA201107530B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI578992B (zh) | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類 |
| JP2014503187A (ja) * | 2010-10-29 | 2014-02-13 | ノクソン ファーマ エージー | 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用 |
| EP4091624A1 (en) * | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| WO2015113776A1 (en) * | 2014-02-03 | 2015-08-06 | Noxxon Pharma Ag | Methods for the preparation of a polyalkoxylated nucleic acid molecule |
| HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| WO2016054411A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| WO2016146587A1 (en) | 2015-03-13 | 2016-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonists for use in the treatment of inflammation |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| KR102687627B1 (ko) | 2016-08-29 | 2024-07-23 | 엘지전자 주식회사 | 냉장고 |
| DE17829597T1 (de) * | 2016-11-30 | 2019-12-05 | Noxxon Pharma Ag | Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2020014646A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7534382B2 (ja) | 2019-07-10 | 2024-08-14 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CA3167751A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2021178923A1 (en) | 2020-03-06 | 2021-09-10 | Drinksavvy, Inc. | Devices and methods for detecting a target analyte of interest |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | インターロイキン－２３受容体のペプチド阻害剤の組成物 |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| WO2023154452A1 (en) | 2022-02-11 | 2023-08-17 | Waypoint Bio, Inc. | Cellular staining probes for analyte detection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) * | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| JPH06508022A (ja) * | 1991-02-21 | 1994-09-14 | ギリアド サイエンシズ，インコーポレイテッド | 生体分子に特異的なアプタマーおよび生産方法 |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US7435542B2 (en) | 2002-06-24 | 2008-10-14 | Cornell Research Foundation, Inc. | Exhaustive selection of RNA aptamers against complex targets |
| US8076306B2 (en) | 2006-04-12 | 2011-12-13 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
| KR101466931B1 (ko) * | 2006-07-18 | 2014-12-02 | 녹손 파르마 아게 | Sdf-1 결합형 b형 핵산분자 |
| EP2066687A4 (en) | 2006-09-21 | 2010-12-08 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE |
| TW201307390A (zh) * | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| TWI578992B (zh) | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類 |
-
2010
- 2010-04-29 TW TW099113693A patent/TWI578992B/zh not_active IP Right Cessation
- 2010-04-30 JP JP2012507644A patent/JP5798549B2/ja not_active Expired - Fee Related
- 2010-04-30 SG SG10201401925VA patent/SG10201401925VA/en unknown
- 2010-04-30 AU AU2010243831A patent/AU2010243831B2/en not_active Ceased
- 2010-04-30 KR KR1020117025594A patent/KR20120004487A/ko not_active Ceased
- 2010-04-30 EP EP10722585A patent/EP2424985A1/en not_active Withdrawn
- 2010-04-30 EA EA201171325A patent/EA022539B1/ru not_active IP Right Cessation
- 2010-04-30 SG SG2011079183A patent/SG175814A1/en unknown
- 2010-04-30 US US13/318,144 patent/US8841431B2/en not_active Expired - Fee Related
- 2010-04-30 CA CA2760244A patent/CA2760244A1/en not_active Abandoned
- 2010-04-30 AR ARP100101478A patent/AR076518A1/es unknown
- 2010-04-30 BR BRPI1014625A patent/BRPI1014625A2/pt not_active IP Right Cessation
- 2010-04-30 CN CN201410657828.4A patent/CN104450691A/zh active Pending
- 2010-04-30 MX MX2011011531A patent/MX2011011531A/es active IP Right Grant
- 2010-04-30 CN CN201080025093.3A patent/CN102459587B/zh not_active Expired - Fee Related
- 2010-04-30 WO PCT/EP2010/002659 patent/WO2010124874A1/en not_active Ceased
-
2011
- 2011-10-13 ZA ZA2011/07530A patent/ZA201107530B/en unknown
- 2011-10-27 IL IL216010A patent/IL216010A0/en unknown
-
2014
- 2014-09-23 US US14/493,435 patent/US20160257958A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5798549B2 (ja) | 2015-10-21 |
| WO2010124874A9 (en) | 2011-10-20 |
| AU2010243831A1 (en) | 2011-11-17 |
| HK1168126A1 (en) | 2012-12-21 |
| EA022539B1 (ru) | 2016-01-29 |
| TW201103549A (en) | 2011-02-01 |
| SG175814A1 (en) | 2011-12-29 |
| US20120053234A1 (en) | 2012-03-01 |
| EP2424985A1 (en) | 2012-03-07 |
| CN104450691A (zh) | 2015-03-25 |
| JP2012525124A (ja) | 2012-10-22 |
| IL216010A0 (en) | 2012-01-31 |
| TWI578992B (zh) | 2017-04-21 |
| CN102459587A (zh) | 2012-05-16 |
| CN102459587B (zh) | 2014-12-10 |
| EA201171325A1 (ru) | 2012-05-30 |
| SG10201401925VA (en) | 2014-10-30 |
| AU2010243831B2 (en) | 2016-03-17 |
| US8841431B2 (en) | 2014-09-23 |
| CA2760244A1 (en) | 2010-11-04 |
| ZA201107530B (en) | 2012-06-27 |
| AR076518A1 (es) | 2011-06-15 |
| WO2010124874A1 (en) | 2010-11-04 |
| BRPI1014625A2 (pt) | 2016-04-05 |
| KR20120004487A (ko) | 2012-01-12 |
| US20160257958A1 (en) | 2016-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011011531A (es) | Acidos nucleicos que se unen a hepcidina. | |
| IL208578A0 (en) | Production of nucleic acid | |
| GB0814570D0 (en) | Isolation of nucleic acid | |
| EP2285973A4 (en) | PROCESS FOR PREPARING METHACRYLIC ACID | |
| ZA201203615B (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| IL218018A0 (en) | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions | |
| SI2421808T1 (sl) | Analogi 4-hidroksi maslene kisline | |
| CL2009000503A1 (es) | Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida. | |
| WO2011142970A3 (en) | Her2 nucleic acid aptamers | |
| WO2013012921A3 (en) | Nucleic acid aptamers | |
| ZA201006719B (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases | |
| UA111142C2 (uk) | Одержання заміщених похідних 2-фторакрилової кислоти | |
| PL2358662T3 (pl) | Sposób amonolizy kwasu 11-bromoundekanowego | |
| WO2013170963A3 (en) | Enzymatic synthesis of l-nucleic acids | |
| EP2609107C0 (en) | PROCESS FOR THE SYNTHESIS OF OLIGORIBONUCLEOTIDES | |
| GB2502195B (en) | Purification of nucleic acids | |
| WO2009153047A3 (de) | Biotechnologische herstellung von acrylsäure | |
| MX2012010443A (es) | Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos. | |
| WO2013030654A8 (en) | Processes for the preparation of (r)-2-acetamido-n-benzyl-3-methoxypropionamide and intermediates thereof | |
| WO2011051976A3 (en) | Process for the preparation of clopidogrel bisulfate form i | |
| GB0816663D0 (en) | Manufacture of fuels | |
| GB201001939D0 (en) | Isolation of nucleic acid | |
| GB201001942D0 (en) | Isolation of nucleic acid | |
| HU0800250D0 (en) | Otuction of glycosid compounds organist acid hydrolyris | |
| GB201016452D0 (en) | Rapid extrection of nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |